Ondansetron Pliva Pharma

Ondansetron, the active ingredient in Ondansetron Pliva Pharma, is a serotonin 5‑HT3 receptor antagonist presented as a tablet for oral use. It is employed to prevent nausea and vomiting associated with chemotherapy, radiotherapy and postoperative recovery in adult and pediatric patients.

GNH USA supplies Ondansetron Pliva Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron acts on the serotonergic pathway to control nausea and vomiting in several clinical settings. - Chemotherapy‑induced nausea and vomiting (CINV): helps reduce both acute and delayed episodes. - Radiation‑induced nausea and vomiting (RINV): provides prophylaxis for patients undergoing radiotherapy. - Post‑operative nausea and vomiting (PONV): decreases the incidence of nausea after surgical procedures.

Adverse reactions to ondansetron are generally mild but can vary in severity.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel movement difficulty. - Diarrhoea: loose stools in a minority of patients. - Fatigue: feeling of tiredness or reduced energy. - Dizziness: transient light‑headed sensations.

Serious or Rare Side Effects: - Cardiac arrhythmia: QT‑interval prolongation, especially with high intravenous doses. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: rare when combined with other serotonergic agents. - Hepatic dysfunction: elevated liver enzymes in susceptible individuals.

When prescribing ondansetron, clinicians should consider several safety aspects. - Cardiac monitoring: assess baseline ECG in patients with known heart disease. - Electrolyte balance: correct hypokalaemia or hypomagnesemia before use. - Drug interactions: review concomitant medications that affect QT interval. - Pregnancy: use only if the potential benefit outweighs risk. - Breastfeeding: monitor infant for possible sedation. Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Ondansetron may interact with other medicines, requiring attention to dosage and monitoring.

Major Interactions (Avoid): - Amiodarone: increased risk of QT prolongation and arrhythmia. - Certain anti‑malarial drugs (e.g., quinidine): additive effect on cardiac repolarisation. - Cis‑cis‑dimethyl‑pyridine (Cis‑DMP): may potentiate serotonergic toxicity.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): potential for serotonin syndrome. - Antifungal azoles (ketoconazole, fluconazole): may increase ondansetron plasma levels. - Macrolide antibiotics (erythromycin): modest effect on QT interval.